Trial Profile

Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results (n=6) assessing safety and efficacy of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Apr 2024 According to a BioXcel Therapeutics media release, the company announced that preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combination with KEYTRUDA in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) has been selected for presentation in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4, 2024 in Chicago, IL.
06 Feb 2024 According to a BioXcel Therapeutics media release, the human proof of concept portion of the trial is expected to start in H1 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com